A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 05 Apr 2018
At a glance
- Drugs ALT 801 (Primary) ; Cisplatin; Gemcitabine
- Indications Urethral cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Altor BioScience Corporation
- 10 Jun 2017 Biomarkers information updated
- 04 Oct 2016 According to Altor BioScience Corporation media release, Status changed from active, no longer recruiting to completed.
- 11 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jul 2017.